Overview

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these results with standard of care enoxaparin. The safety of betrixaban will also be studied.
Phase:
Phase 3
Details
Lead Sponsor:
Portola Pharmaceuticals
Treatments:
Betrixaban
Enoxaparin